Search results for "Organoplatinum Compound"

showing 10 items of 83 documents

Pharmacokinetic and metabolism determinants of fluoropyrimidines and oxaliplatin activity in treatment of colorectal patients

2011

Fluoropyrimidines and oxaliplatin continued to be the mainstay of therapeutic regimens in the treatment of colorectal cancer (CRC). For this reason, pharmacokinetic and metabolism of these drugs were analyzed and the identification of accurate and validated predictive, prognostic and toxicity markers became necessary to develop an effective therapy adapted to the patient's molecular profile, while minimizing life-threatening toxicities. In this review, we discuss literature data, defining predictive and prognostic markers actually identified in the treatment of CRC. We analyzed predictive markers of fluoropyrimidines effectiveness, principally for 5-Fluorouracil (5-FU) and also for oral flu…

Oncologymedicine.medical_specialtyOrganoplatinum CompoundsColorectal cancerSettore MED/06 - Oncologia Medica5-FluorouracilPredictive markerClinical BiochemistryAntineoplastic AgentsPharmacologyThymidylate synthaseXRCC1Internal medicinemedicineDihydropyrimidine dehydrogenaseBiomarkers TumorHumans5-Fluorouracil; Dihydropyrimidine dehydrogenase; Glutathione S-transferase; Nucleotide excision repair; Oxaliplatin; Predictive marker; Thymidylate Synthase; Toxicity marker; Pharmacology; Clinical BiochemistryPharmacologyPredictive markerbiologyMicrosatellite instabilityThymidylate Synthasemedicine.diseaseToxicity markerOxaliplatinGlutathione S-transferaseOxaliplatinNucleotide excision repairPyrimidinesbiology.proteinERCC1Colorectal NeoplasmsDihydropyrimidine dehydrogenasemedicine.drug
researchProduct

Does neoadjuvant FOLFOX chemotherapy improve the prognosis of high‐risk Stage II and III colon cancers? Three years' follow‐up results of the PRODIGE…

2021

International audience; Aim Neoadjuvant chemotherapy has proven valuable in locally advanced resectable colon cancer (CC) but its effect on oncological outcomes is uncertain. The aim of the present paper was to report 3-year oncological outcomes, representing the secondary endpoints of the PRODIGE 22 trial. Method PRODIGE 22 was a randomized multicentre phase II trial in high-risk T3, T4 and/or N2 CC patients on CT scan. Patients were randomized between 6 months of adjuvant FOLFOX (upfront surgery) or perioperative FOLFOX (four cycles before surgery and eight cycles after; FOLFOX perioperative). In wild-type RAS patients, a third arm testing perioperative FOLFOX-cetuximab was added. The pri…

Oncologymedicine.medical_specialtyOrganoplatinum CompoundsColorectal cancer[SDV]Life Sciences [q-bio]medicine.medical_treatmentPopulationLeucovorinsurvival03 medical and health sciences0302 clinical medicineFOLFOXInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumanseducationNeoplasm StagingColectomyeducation.field_of_studybusiness.industryHazard ratioGastroenterologyPerioperativecolectomyPrognosisInterim analysismedicine.diseaseNeoadjuvant Therapydigestive system diseasescolon cancerChemotherapy Adjuvant030220 oncology & carcinogenesisColonic Neoplasms030211 gastroenterology & hepatologyFluorouracilNeoplasm Recurrence Localbusinessneoadjuvant chemotherapyFollow-Up Studiesmedicine.drugColorectal Disease
researchProduct

Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK …

2013

Background: Combined inhibition of platelet-derived growth factor receptor beta signalling and vascular endothelial growth factor promotes vascular normalisation in preclinical models and may lead to increased delivery of chemotherapy to tumour tissue. This phase I/II trial assessed the safety and efficacy of capecitabine plus oxaliplatin (XELOX) plus bevacizumab and imatinib in the first-line treatment of patients with metastatic colorectal cancer. Methods: Two dose levels (I/II) were defined: capecitabine 850/1000 mg m−2 twice daily on days 1–14; oxaliplatin 100/130 mg m−2 on day 1; bevacizumab 7.5 mg kg−1 on day 1; imatinib 300 mg day−1 on days 1–21 every 21 days. The primary study endpo…

OncologysafetyAdultMaleCancer Researchmedicine.medical_specialtyBevacizumabOrganoplatinum CompoundsColorectal cancermedicine.medical_treatmentcolorectal cancerbevacizumabAntibodies Monoclonal HumanizedDeoxycytidineDisease-Free SurvivalDrug Administration SchedulePiperazinesCapecitabineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansProspective StudiesCapecitabineAgedAged 80 and overChemotherapybusiness.industrySunitiniboxaliplatinMiddle Agedmedicine.diseaseSurgeryOxaliplatinImatinib mesylatePyrimidinesTreatment OutcomeOncologyimatinibFluorouracilBenzamidesClinical StudyImatinib MesylateFemaleFluorouracilbusinessColorectal Neoplasmsmedicine.drugBritish Journal of Cancer
researchProduct

Bcl-xL and Myeloid cell leukaemia-1 contribute to apoptosis resistance of colorectal cancer cells

2008

AIM: To explore the role of Bcl-x(L) and Myeloid cell leukaemia (Mcl)-1 for the apoptosis resistance of colorectal carcinoma (CRC) cells towards current treatment modalities. METHODS: Bcl-x(L) and Mcl-1 mRNA and protein expression were analyzed in CRC cell lines as well as human CRC tissue by Western blot, quantitative PCR and immunohistochemistry. Bcl-x(L) and Mcl-1 protein expression was knocked down or increased in CRC cell lines by applying specific siRNAs or expression plasmids, respectively. After modulation of protein expression, CRC cells were treated with chemotherapeutic agents, an antagonistic epidermal growth factor receptor (EGFR1) antibody, an EGFR1 tyrosine kinase inhibitor, …

Organoplatinum CompoundsCell SurvivalCellbcl-X ProteinAntineoplastic AgentsApoptosisBcl-xLAdenocarcinomaBiologyIrinotecanTNF-Related Apoptosis-Inducing LigandDownregulation and upregulationhemic and lymphatic diseasesCell Line TumormedicineHumansRNA Messengerfas ReceptorViability assayneoplasmsColorectal CancerGastroenterologyGeneral MedicineTransfectionFas receptorMolecular biologydigestive system diseasesErbB ReceptorsOxaliplatinmedicine.anatomical_structureProto-Oncogene Proteins c-bcl-2ApoptosisCell cultureCancer researchbiology.proteinMyeloid Cell Leukemia Sequence 1 ProteinCamptothecinFluorouracilColorectal NeoplasmsWorld Journal of Gastroenterology
researchProduct

DNA Binding Studies and Cytotoxicity of a Dinuclear PtII Diazapyrenium- Based Metallo-supramolecular Rectangular Box

2012

The interaction with native DNA of a 2,7-diazapyrenium-based ligand 1 and its Pt II rectangular metal- lacycle 2 is explored through circular and linear dichroism and fluorescence spectroscopies. The metal-free ligand 1 binds through intercalation, with a binding constant of approximately 5 � 10 5 m � 1 , whereas the metallacycle 2 binds and bends the DNA with a bind- ing constant of 7 � 10 6 m � 1 . PCR assays show that metallo-supramolecular box 2 interferes with DNA transactions in vitro whereas the intercalator 1 does not. The metallacycle is active against four human cancer cell lines, with IC50 values ranging between 3.1 and 19.2 mm and shows similar levels of efficacy, but a differen…

Organoplatinum CompoundsCell SurvivalStereochemistryIntercalation (chemistry)Molecular ConformationSupramolecular chemistryAntineoplastic AgentsApoptosisLigandsNucleic Acid DenaturationLinear dichroismCatalysissupramolecular chemistryInhibitory Concentration 50chemistry.chemical_compoundCell Line TumorSettore BIO/10 - BiochimicaHumansmetallodrugPlatinumnoncovalent DNA bindingChemistryCircular DichroismOrganic ChemistryDNA NeoplasmGeneral ChemistrySettore CHIM/06 - Chimica OrganicaMetallacycleLigand (biochemistry)Binding constantFluorescenceSettore CHIM/08 - Chimica FarmaceuticaIntercalating AgentsKineticsSpectrometry FluorescenceSettore CHIM/03 - Chimica Generale E InorganicaThermodynamicscytotoxicityPtII rectangular boxCisplatinDNAPhenanthrolines
researchProduct

Expression of a mutant HSP110 sensitizes colorectal cancer cells to chemotherapy and improves disease prognosis

2011

Heat shock proteins (HSPs) are necessary for cancer cell survival. We identified a mutant of HSP110 (HSP110ΔE9) in colorectal cancer showing microsatellite instability (MSI CRC), generated from an aberrantly spliced mRNA and lacking the HSP110 substrate-binding domain. This mutant was expressed at variable levels in almost all MSI CRC cell lines and primary tumors tested. HSP110ΔE9 impaired both the normal cellular localization of HSP110 and its interaction with other HSPs, thus abrogating the chaperone activity and antiapoptotic function of HSP110 in a dominant-negative manner. HSP110ΔE9 overexpression caused the sensitization of cells to anticancer agents such as oxaliplatin and 5-fluorou…

Organoplatinum CompoundsColorectal cancermedicine.medical_treatment[SDV]Life Sciences [q-bio]Blotting WesternFluorescent Antibody TechniqueAntineoplastic AgentsBiologyBioinformaticsReal-Time Polymerase Chain ReactionTransfectionGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicineHeat shock proteinCell Line TumormedicineHumansImmunoprecipitationHSP110 Heat-Shock ProteinsneoplasmsCellular localizationComputingMilieux_MISCELLANEOUS030304 developmental biologyDNA Primers0303 health sciencesChemotherapyMicrosatellite instabilityGeneral MedicineTransfectionmedicine.diseasePrognosisdigestive system diseases3. Good healthOxaliplatinOxaliplatin030220 oncology & carcinogenesisCancer cellMutationCancer researchRegression AnalysisMicrosatellite InstabilityFluorouracilColorectal Neoplasmsmedicine.drugPlasmids
researchProduct

Survivin is regulated by interleukin-4 in colon cancer stem cells

2010

Colorectal cancer has provided an important model to test the stem cell hypothesis of cancer origin, which implies that cancer arises as a result of genetic aberrations in stem cells leading to deregulation of the proliferation/differentiation balance. We and others have demonstrated that, similarly to other solid tumors, colon carcinogenesis and progression are dictated by highly apoptosis-resistant stem-like cells. Our data have suggested that protection from apoptosis is achieved by autocrine production of interleukin-4 (IL-4) through up-regulation of anti-apoptotic mediators. In this study, we extend our analysis to another apoptosis inhibitor widely expressed in tumors, namely survivin…

Organoplatinum CompoundsPhysiologyColorectal cancerSurvivinmedicine.medical_treatmentClinical BiochemistryFluorescent Antibody TechniqueAntineoplastic AgentsApoptosisBiologyInhibitor of Apoptosis ProteinsSurvivin inetrleukin-4Cancer stem cellSurvivinIn Situ Nick-End LabelingmedicineHumansPhosphorylationAutocrine signallingInterleukin 4Staining and LabelingCancerIsoxazolesCell Biologymedicine.diseaseGene Expression Regulation NeoplasticOxaliplatinProtein TransportCytokineImmunologyNeoplastic Stem CellsCancer researchInterleukin-4Stem cellColorectal NeoplasmsSTAT6 Transcription FactorMicrotubule-Associated ProteinsLeflunomideJournal of Cellular Physiology
researchProduct

New heteronuclear gold(I)-platinum(II) complexes with cytotoxic properties: are two metals better than one?

2014

A series of mono- and heterodinuclear gold(I) and platinum(II) complexes with a new bipyridylamine-phosphine ligand have been synthesized and characterized. The X-ray structures of the ligand precursor 4-iodo-N,N-di(pyridin-2-yl)benzamide, and of one gold derivative are reported. All the complexes display antiproliferative properties in vitro in human cancer cells in the range of cisplatin or higher, which appear to correlate with compounds' uptake. Interestingly, studies of the interactions of the compounds with models of DNA indicate different mechanisms of actions with respect to cisplatin. The biological activity study of these complexes provides useful information about the interest of…

Organoplatinum CompoundsStereochemistryCell SurvivalPhosphinesPyridinesthioglucoseGOLD COMPOUNDSchemistry.chemical_elementAntineoplastic AgentsPLATINUM COMPLEXESBiochemistryRutheniumInorganic Chemistrychemistry.chemical_compoundStructure-Activity RelationshipGold CompoundsCoordination ComplexesCell Line TumormedicineHumansDNA bindingBenzamideBIOLOGICAL-PROPERTIESCell ProliferationCisplatinheteronuclear complexDERIVATIVESChemistryLigandCytotoxinsBiological activityBiological TransportDNAPYRIDINEanticancer agentRutheniumHeteronuclear moleculepolymerizationBenzamidesLIGANDSCisplatinGold complexesPlatinumOrganogold Compoundsmedicine.drugPlasmidsJournal of inorganic biochemistry
researchProduct

cis-Dichloroplatinum(II) complexes tethered to dibenzo[c,h][1,6]naphthyridin-6-ones: Synthesis and cytotoxicity in human cancer cell lines in vitro

2013

A novel family of cisplatin-type complexes tethered to dibenzo[c,h][1,6]naphthyridin-6-one topoisomerase inhibitor via a polymethylene chain and their nonplatinated counterparts were prepared. Their potential cytotoxicity was assessed in three human colorectal cancer cell lines HCT 116, SW480 and HT-29 and compared to the reference molecules cisplatin and oxaliplatin. Platinated compounds were poorly active whilst nonplatinated dibenzo[c,h][1,6]naphthyridin-6-one moieties exhibited higher cytotoxic properties than cisplatin and oxaliplatin whatever the length of the polymethylene chain; molecules containing the tri- and hexamethylene chain length were the most cytotoxic.

Organoplatinum Compoundsmedicine.drug_classStereochemistryAntineoplastic AgentsStructure-Activity RelationshipCell Line TumorDrug DiscoverymedicineHumansCytotoxic T cellMoleculeNaphthyridinesCytotoxicityCell ProliferationPharmacologyCisplatinDose-Response Relationship DrugMolecular StructureChemistryOrganic ChemistryGeneral MedicineHCT116 CellsIn vitroOxaliplatinCell cultureDrug Screening Assays AntitumorHT29 CellsTopoisomerase inhibitormedicine.drugEuropean Journal of Medicinal Chemistry
researchProduct

Cardiac Glycosides Exert Anticancer Effects by Inducing Immunogenic Cell Death

2012

Some successful chemotherapeutics, notably anthracyclines and oxaliplatin, induce a type of cell stress and death that is immunogenic, hence converting the patient's dying cancer cells into a vaccine that stimulates antitumor immune responses. By means of a fluorescence microscopy platform that allows for the automated detection of the biochemical hallmarks of such a peculiar cell death modality, we identified cardiac glycosides (CGs) as exceptionally efficient inducers of immunogenic cell death, an effect that was associated with the in- hibition of the plasma membrane Na + - and K + -dependent adenosine triphosphatase (Na + /K + -ATPase). CGs ex- acerbated the antineoplastic effects of DN…

Programmed cell deathDigoxinOrganoplatinum Compoundsmedicine.medical_treatment[SDV]Life Sciences [q-bio]Antineoplastic AgentsBiosensing TechniquesBiologyPharmacologyCardiac Glycosides03 medical and health sciencesMice0302 clinical medicineImmune systemCell Line TumorNeoplasmsmedicineAnimalsHumansAnthracyclinesComputingMilieux_MISCELLANEOUS030304 developmental biology0303 health sciencesChemotherapyGeneral Medicinemedicine.disease3. Good healthOxaliplatinOxaliplatinCell culture030220 oncology & carcinogenesisHepatocellular carcinomaCancer cellImmunogenic cell deathmedicine.drug
researchProduct